vs
Embecta Corp.（EMBC）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Embecta Corp.的季度营收约是Rapid7, Inc.的1.2倍（$261.2M vs $217.4M），Embecta Corp.净利率更高（16.9% vs 1.4%，领先15.4%），Rapid7, Inc.同比增速更快（0.5% vs -0.3%），Rapid7, Inc.自由现金流更多（$36.4M vs $16.6M），过去两年Rapid7, Inc.的营收复合增速更高（3.0% vs -4.6%）
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
EMBC vs RPD — 直观对比
营收规模更大
EMBC
是对方的1.2倍
$217.4M
营收增速更快
RPD
高出0.8%
-0.3%
净利率更高
EMBC
高出15.4%
1.4%
自由现金流更多
RPD
多$19.8M
$16.6M
两年增速更快
RPD
近两年复合增速
-4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $261.2M | $217.4M |
| 净利润 | $44.1M | $3.1M |
| 毛利率 | 61.9% | 68.9% |
| 营业利润率 | 31.9% | 1.0% |
| 净利率 | 16.9% | 1.4% |
| 营收同比 | -0.3% | 0.5% |
| 净利润同比 | — | 44.1% |
| 每股收益（稀释后） | $0.74 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMBCRPD
| Q4 25 | $261.2M | $217.4M | ||
| Q3 25 | $264.0M | $218.0M | ||
| Q2 25 | $295.5M | $214.2M | ||
| Q1 25 | $259.0M | $210.3M | ||
| Q4 24 | $261.9M | $216.3M | ||
| Q3 24 | $286.1M | $214.7M | ||
| Q2 24 | $272.5M | $208.0M | ||
| Q1 24 | $287.2M | $205.1M |
净利润EMBCRPD
| Q4 25 | $44.1M | $3.1M | ||
| Q3 25 | $26.4M | $9.8M | ||
| Q2 25 | $45.5M | $8.3M | ||
| Q1 25 | $23.5M | $2.1M | ||
| Q4 24 | $0 | $2.2M | ||
| Q3 24 | $14.6M | $15.4M | ||
| Q2 24 | $14.7M | $6.5M | ||
| Q1 24 | $28.9M | $1.4M |
毛利率EMBCRPD
| Q4 25 | 61.9% | 68.9% | ||
| Q3 25 | 60.0% | 70.2% | ||
| Q2 25 | 66.7% | 70.6% | ||
| Q1 25 | 63.4% | 71.7% | ||
| Q4 24 | 60.0% | 69.5% | ||
| Q3 24 | 60.7% | 70.6% | ||
| Q2 24 | 69.8% | 70.7% | ||
| Q1 24 | 64.6% | 70.3% |
营业利润率EMBCRPD
| Q4 25 | 31.9% | 1.0% | ||
| Q3 25 | 21.4% | 2.7% | ||
| Q2 25 | 31.8% | 1.6% | ||
| Q1 25 | 24.3% | -0.0% | ||
| Q4 24 | 11.0% | 3.4% | ||
| Q3 24 | 9.2% | 6.0% | ||
| Q2 24 | 20.5% | 2.5% | ||
| Q1 24 | 13.6% | 4.7% |
净利率EMBCRPD
| Q4 25 | 16.9% | 1.4% | ||
| Q3 25 | 10.0% | 4.5% | ||
| Q2 25 | 15.4% | 3.9% | ||
| Q1 25 | 9.1% | 1.0% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | 5.1% | 7.2% | ||
| Q2 24 | 5.4% | 3.1% | ||
| Q1 24 | 10.1% | 0.7% |
每股收益（稀释后）EMBCRPD
| Q4 25 | $0.74 | $0.05 | ||
| Q3 25 | $0.44 | $0.15 | ||
| Q2 25 | $0.78 | $0.13 | ||
| Q1 25 | $0.40 | $0.03 | ||
| Q4 24 | $0.00 | $0.08 | ||
| Q3 24 | $0.24 | $0.21 | ||
| Q2 24 | $0.25 | $0.09 | ||
| Q1 24 | $0.50 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.3M | $474.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-613.1M | $154.7M |
| 总资产 | $1.1B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EMBCRPD
| Q4 25 | $201.3M | $474.7M | ||
| Q3 25 | $225.5M | $407.1M | ||
| Q2 25 | $230.6M | $511.7M | ||
| Q1 25 | $209.3M | $493.5M | ||
| Q4 24 | $210.0M | $521.7M | ||
| Q3 24 | $267.5M | $443.7M | ||
| Q2 24 | $275.1M | $442.6M | ||
| Q1 24 | $299.8M | $411.7M |
总债务EMBCRPD
| Q4 25 | — | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EMBCRPD
| Q4 25 | $-613.1M | $154.7M | ||
| Q3 25 | $-650.6M | $127.2M | ||
| Q2 25 | $-669.6M | $90.4M | ||
| Q1 25 | $-736.2M | $52.7M | ||
| Q4 24 | $-768.8M | $17.7M | ||
| Q3 24 | $-738.3M | $-5.1M | ||
| Q2 24 | $-763.7M | $-52.6M | ||
| Q1 24 | $-769.6M | $-86.4M |
总资产EMBCRPD
| Q4 25 | $1.1B | $1.7B | ||
| Q3 25 | $1.1B | $1.7B | ||
| Q2 25 | $1.2B | $1.6B | ||
| Q1 25 | $1.1B | $1.6B | ||
| Q4 24 | $1.1B | $1.7B | ||
| Q3 24 | $1.3B | $1.6B | ||
| Q2 24 | $1.3B | $1.5B | ||
| Q1 24 | $1.2B | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.2M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $16.6M | $36.4M |
| 自由现金流率自由现金流/营收 | 6.4% | 16.8% |
| 资本支出强度资本支出/营收 | 0.2% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.39× | 12.01× |
| 过去12个月自由现金流最近4个季度 | $205.8M | $146.2M |
8季度趋势，按日历期对齐
经营现金流EMBCRPD
| Q4 25 | $17.2M | $37.6M | ||
| Q3 25 | $84.0M | $39.0M | ||
| Q2 25 | $81.2M | $47.5M | ||
| Q1 25 | $31.8M | $29.8M | ||
| Q4 24 | $-5.3M | $63.8M | ||
| Q3 24 | $26.6M | $44.0M | ||
| Q2 24 | $-2.1M | $32.9M | ||
| Q1 24 | $24.3M | $31.1M |
自由现金流EMBCRPD
| Q4 25 | $16.6M | $36.4M | ||
| Q3 25 | $76.7M | $34.8M | ||
| Q2 25 | $80.8M | $46.6M | ||
| Q1 25 | $31.7M | $28.4M | ||
| Q4 24 | $-6.8M | $62.6M | ||
| Q3 24 | — | $42.6M | ||
| Q2 24 | $-11.8M | $32.6M | ||
| Q1 24 | $20.9M | $30.4M |
自由现金流率EMBCRPD
| Q4 25 | 6.4% | 16.8% | ||
| Q3 25 | 29.1% | 16.0% | ||
| Q2 25 | 27.3% | 21.8% | ||
| Q1 25 | 12.2% | 13.5% | ||
| Q4 24 | -2.6% | 28.9% | ||
| Q3 24 | — | 19.9% | ||
| Q2 24 | -4.3% | 15.7% | ||
| Q1 24 | 7.3% | 14.8% |
资本支出强度EMBCRPD
| Q4 25 | 0.2% | 0.5% | ||
| Q3 25 | 2.8% | 1.9% | ||
| Q2 25 | 0.1% | 0.4% | ||
| Q1 25 | 0.0% | 0.6% | ||
| Q4 24 | 0.6% | 0.5% | ||
| Q3 24 | 0.0% | 0.6% | ||
| Q2 24 | 3.6% | 0.1% | ||
| Q1 24 | 1.2% | 0.3% |
现金转化率EMBCRPD
| Q4 25 | 0.39× | 12.01× | ||
| Q3 25 | 3.18× | 3.97× | ||
| Q2 25 | 1.78× | 5.70× | ||
| Q1 25 | 1.35× | 14.14× | ||
| Q4 24 | — | 29.36× | ||
| Q3 24 | 1.82× | 2.85× | ||
| Q2 24 | -0.14× | 5.03× | ||
| Q1 24 | 0.84× | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
